Talphera, Inc. (NASDAQ:TLPH) Short Interest Down 51.1% in November

Talphera, Inc. (NASDAQ:TLPH) saw a significant drop in short interest during the month of November. As of November 30th, there was short interest totalling 41,900 shares, a drop of 51.1% from the November 15th total of 85,600 shares. Based on an average daily trading volume, of 99,700 shares, the short-interest ratio is currently 0.4 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TLPH. Nantahala Capital Management LLC acquired a new position in Talphera in the second quarter valued at approximately $1,773,000. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Talphera in the 2nd quarter valued at $64,000. Finally, Rosalind Advisors Inc. acquired a new position in shares of Talphera during the 3rd quarter valued at $650,000. 37.67% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Maxim Group upgraded Talphera to a “strong-buy” rating in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Talphera in a research report on Friday, August 16th.

Talphera Stock Performance

Shares of Talphera stock traded down $0.01 during trading on Friday, reaching $0.65. 62,975 shares of the company’s stock were exchanged, compared to its average volume of 91,149. Talphera has a 1-year low of $0.62 and a 1-year high of $1.61. The company has a market cap of $11.07 million, a P/E ratio of -0.94 and a beta of 0.25. The firm’s 50-day moving average price is $0.82 and its 200 day moving average price is $0.89.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.